Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis
Pooled result · Percentage body weight change from baselineResult — go to the resultMD −12.04 % 95% CI −13.08 to −11.00Authors' conclusion
Subcutaneous semaglutide is effective for weight management in adults with overweight or obesity without diabetes.
Study context
- Population
- Adults with overweight or obesity without diabetes
- Participants
- 6,239 adults9 trials
- Comparison
- Subcutaneous semaglutide vs placebo
- Outcome
- Percentage body weight change from baseline
Pooled result
As reported in the abstract
MD
−12.04 %
95% CI −13.08 to −11.00
P < 0.00001
Semaglutidevs Placebo
MD −12.04 % (95% CI −13.08 to −11.00); P < 0.00001
Further pooled results
| Outcome | MD (cm) (95% CI) | P value | |
|---|---|---|---|
| Waist circumference | −9.36 (−10.27 to −8.45) | P < 0.00001 | |
| −15−10−505Difference, cm (linear scale) |
| Outcome | MD (%) (95% CI) | P value | |
|---|---|---|---|
| CRP | −40.90 (−46.37 to −35.42) | P < 0.00001 | |
| −60−40−20020Difference, % (linear scale) |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Serious adverse events | 1.12 (0.76–1.65) | P = 0.55 | |
| 0.512Relative risk (log scale) |
Original publication
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis. Int J Obes (Lond). Published 29 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →